In AML, the blockade of IL-8 binding to CXCR2 using a novel experimental inhibitor (NCI34255) led to a reversal of therapy resistance [42], highlighting a means of therapeutically targeting IL-8/CXCR2 signalling in CML. This evidence concerns the gene CXCR2 and acute myeloid leukemia.